MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that its AbD Serotec business unit has received a multiple research antibody order from Proteomika SL, a Spanish biotechnology company specializing in biomarker discovery. Proteomika has ordered novel, HuCAL-based, research antibodies against a broad range of target molecules in addition to the production of antigen material at AbD Serotec. AbD Serotec will apply MorphoSys's HuCAL GOLD antibody technology and the proprietary Antigen Expression System AgX(TM). The order ranks Proteomika among the largest customers for custom monoclonals services provided by AbD Serotec. Financial details of the agreement were not disclosed.

 

Proteomika was established in 2002 as a subsidiary of the leading genomics company Progenika Biopharma SA with the objective of exploiting advances in biomarker research for the development of diagnostic and prognostic products. The company has established research collaborations with numerous pharmaceutical and biotechnology companies aimed at the discovery and validation of non-invasive diagnostic and pharmacoproteomics markers as well as identifying novel therapeutic targets. Additionally, Proteomika is actively involved in in-house discovery projects at the bioGUNE Research Institute in cancer and other disease areas.

 

In announcing this agreement Dr. Laureano Simon, Chief Executive Officer of Proteomika, said 'Proteomika is delighted to announce this agreement with AbD Serotec - the industry leader in providing tailored antibodies for research applications. The fast turn around in antibody production offered by AbD Serotec, together with the high quality of the resulting antibodies, will help accelerate the process of biomarker identification and validation, allowing Proteomika to bring new diagnostic and prognostic tools for human diseases to the market in the shortest possible timeframe.'

 

'We welcome the decision of Proteomika to use HuCAL GOLD research antibodies in its proteomics programs,' commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. 'This order is one of the largest generated by AbD Serotec, and highlights the advantage of our HuCAL technology in bespoke proteomics applications.'

 

For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Manager Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-454, brkulj@morphosys.com